Part of the article also suggests that where efficacy is limited in vivo yet successful in vitro, it may be a delivery aspect that is needed, a method to enter the cells the currently doesnt exist under natural circumstances, a carrier, which allows collaborators to research if they have a vehicle that could get ATL-1102 inside the cells in vivo that dont naturally receive them. Which could, open up new areas of disease effect, and expanding the platform.
Reearch can just keep branching out in so many directions.
Some insights into backend work with ATL-1102, page-14
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 194063 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |